As we age, our vision undergoes natural changes, including difficulty focusing on near objects (presbyopia) and reduced light ...

"Lento Bio's innovative approach to treating the underlying cause of presbyopia would, if approved, broaden the therapeutic options for the most common refractive condition, impacting billions of ...

On Thursday, the U.S. Food and Drug Administration approved LENZ Therapeutics, Inc.’s (NASDAQ:LENZ) VIZZ (aceclidine ophthalmic solution, previously known as LNZ100) 1.44%, the first and only ...

The FDA has approved VIZZ eye drops (LENZ Therapeutics, Inc.) for the treatment of presbyopia, the gradual loss of near vision associated with aging that affects nearly 130 million American adults.

VIZZ is the first and only aceclidine-based eye drop approved to improve near vision in adults with presbyopia, a condition impacting approximately 128 million adults in the United States First once ...

Getting older sucks, and part of that suck is having your vision slowly get worse, but one company may have a temporary fix ...